Skip to main content

Table 1 Selected EWAS CpG sites for pretreatment, posttreatment, and gene–drug interactions (p value <1E-5 is considered statistical signifiance and italicized)

From: Modification effect of fenofibrate therapy, a longitudinal epigenomic-wide methylation study of triglycerides levels in the GOLDN study

CpG site Chr Location Genes Pretreatment β1 (95% CI) Posttreatment β1 + δ (95% CI) Modification effect (95% CI) p value (Pre-) p value (Post-) p value (Modif.)
Significant effect modification sites
 cg20015535 1 231,556,123 EGLN1 1.30 (0.11, 2.49) −3.1 (−4.77, −1.43) − 4.4 (−6.17, − 2.63) 3.31E-02 2.80E-04 1.49E-06
 cg24870738 1 45,097,499 RNF220 −3.8 (−5.9, −1.70) 2.23 (0.58, 3.88) 6.03 (3.44, 8.62) 4.40E-04 7.81E-03 6.90E-06
 cg06891775 10 80,704,982 LOC283050 2.13 (1.28, 2.98) 0.52 (−0.29, 1.33) −1.61 (−2.3, − 0.92) 1.39E-06 2.10E-01 5.91E-06
 cg00607630 16 9,030,093 USP7 2.82 (1.61, 4.03) 0.04 (−1.15, 1.23) −2.78 (−3.97, −1.59) 7.18E-06 9.53E-01 6.60E-06
Significant pre or post methylation sites
 cg03725309 1 109,757,585 SARS −1.65 (−2.18, − 1.12) − 1.28 (− 1.85, −0.71) 0.37 (0.04, 0.7) 3.00E-09 9.82E-06 2.50E-02
 cg12556569 11 116,664,039 APOA5 0.35 (0.23, 0.47) 0.23 (0.08, 0.38) −0.12 (−0.24, 0) 3.11E-08 2.34E-03 4.56E-02
 cg11376147 11 57,261,198 SLC43A1 −2.24 (−3.01, −1.47) −1.46 (− 2.37, −0.55) 0.78 (0, 1.56) 2.46E-08 1.60E-03 5.20E-02
 cg00574958 11 68,607,622 CPT1A −3.81 (−4.44, − 3.18) − 3.55 (−4.26, −2.84) 0.26 (−0.31, 0.83) 2.12E-28 1.07E-22 3.65E-01
 cg01082498 11 68,608,225 CPT1A −2.59 (−3.48, −1.7) −2.38 (−3.39, − 1.37) 0.21 (−0.66, 1.08) 1.86E-08 3.83E-06 6.30E-01
 cg17058475 11 68,607,737 CPT1A −2.31 (−2.84, −1.78) −2.34 (− 2.94, − 1.74) −0.04 (−0.45, 0.37) 5.00E-16 1.91E-14 8.63E-01
 cg06500161 21 43,656,587 ABCG1 2.26 (1.45, 3.07) 2.16 (1.21, 3.11) −0.09 (−0.86, 0.68) 7.55E-08 8.18E-06 8.16E-01
\